💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Erlotinib Hydrochloride

CHEMBL1079742 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
429.9 g/mol
LogP
—
Phase
4

Reversible inhibition of the epidermal growth factor receptor tyrosine kinase is the pharmacology of erlotinib hydrochloride, which prevents receptor autophosphorylation and thereby interrupts downstream proliferative signalling. Tumours carrying activating EGFR mutations depend on that pathway, and it is in such tumours that the agent slows growth. The hydrochloride salt is the form presented in standard oral capsules, chosen for pharmaceutical rather than pharmacological reasons. Reversibility of binding distinguishes this generation of EGFR inhibitors from the covalent agents developed subsequently. The salt has the formula C22H24ClN3O4 and a molecular weight of approximately 429.9 g/mol, and it is approved with development completed through the final phase.

The hydrochloride salt form of erlotinib, this targeted cancer drug blocks the EGFR signaling pathway to slow the growth of EGFR-mutated tumors. The hydrochloride salt formulation is used in standard oral capsules.

分子量

429.9000 g/mol

TPSA

74.70 Ų

治療領域

Oncology

作用機序

Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H24ClN3O4

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
回転可能結合数

                        
11

                    

                    
                    
                    

                        
重原子数

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
The hydrochloride salt form of erlotinib, this targeted cancer drug blocks the EGFR signaling pathway to slow the growth of EGFR-mutated tumors. The hydrochloride salt formulation is used in standard oral capsules.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Erlotinib Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1079742.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 176871.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.